Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6052W HIGH $10.00
Volume
585.34 K
Value Traded
1.08 M
Short % Float
12.45%
Days to Cover
3.0
-28.57%Week
-45.39%1 Month
-38.46%3 Month
-56.76%6 Month
-91.34%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
24.19 M
EPS (TTM)
-2.01
P/E Ratio
-
Ent. Value
-747.62 K
Total Shares
15.12 M
Float Shares
9.70 M
Insiders
35.84%
Institutions
22.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CRVO Catalyst Timeline
Dated clinical, regulatory and corporate events for CervoMed Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CervoMed Inc.
224Total events
15Upcoming
23Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
●PublicationNeflamapimodPresentation
RewinD-LB placebo-controlled Phase 2b results published in Alzheimer's Research & Therapy
Dementia with Lewy Bodies (DLB)source ↗
▲Oral PresentationNeflamapimodPresentation
Initial Phase 2a nfvPPA biomarker results presented in late-breaking oral session at ISFTD 2026
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
▲Biomarker DataNeflamapimodClinical Data
Initial 12-week plasma NfL/GFAP biomarker results from Phase 2a nfvPPA trial
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
▲Enrollment CompleteNeflamapimodTrial
Enrollment completed in Phase 2a trial of neflamapimod in nfvPPA
nfvPPAsource ↗
▲PK PD DataNeflamapimodClinical Data
Phase 1 food-effect/drug-exposure study of new 50 mg neflamapimod tablet met primary objectives
▲Manufacturing MilestoneNeflamapimodCMC / Inspection
Implementation of controlled manufacturing process for neflamapimod 50 mg tablet
▲FDA Feedback ReceivedNeflamapimodFDA Meeting
FDA removed plasma drug exposure limit constraining neflamapimod dosing
●R&D DayPresentation
CervoMed to participate in Cantor Global Healthcare Conference fireside chat
▲Enrollment CompleteNeflamapimodTrial
CervoMed completed enrollment in Phase 2a trial of neflamapimod in nfvPPA
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
▲MHRA ILAPNeflamapimodEx-US Regulatory
Neflamapimod awarded Innovation Passport under UK ILAP for DLB
Dementia with Lewy Bodies (DLB)source ↗
▲MHRA ILAPNeflamapimodEx-US Regulatory
Neflamapimod awarded Innovation Passport designation under UK ILAP for DLB
dementia with Lewy bodies (DLB)source ↗
▲Other Regulator MilestoneNeflamapimodEx-US Regulatory
Awarded Innovation Passport under UK ILAP for DLB
dementia with Lewy bodies (DLB)source ↗
◆Oral PresentationNeflamapimodPresentation
Presentation of new clinical, plasma biomarker and imaging data at AAIC 2026
Dementia with Lewy Bodiessource ↗
▼Topline ReadoutNeflamapimodClinical Data
Phase 2b topline results: did not replicate Phase 2a positive results on CDR-SB
Dementia with Lewy Bodiessource ↗
▲Primary Endpoint MetNeflamapimodClinical Data
Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives
Dementia with Lewy Bodiessource ↗
◆Poster PresentationNeflamapimodPresentation
Poster presentations of results accessible on website
Dementia with Lewy Bodiessource ↗
▲Enrollment CompleteNeflamapimodTrial
Completed enrollment in Phase 2a study of neflamapimod for nfvPPA
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
▲Enrollment CompleteNeflamapimodTrial
Completed enrollment in Phase 2a nfvPPA trial
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
●Oral PresentationNeflamapimodPresentation
Clinical data for neflamapimod 80 mg BID presented at Alzheimer's Association International Conference
dementia with Lewy bodiessource ↗
▼Equity OfferingCorporate
Closed $10 million registered direct offering of common stock at $4.00 per share
▲Enrollment CompleteNeflamapimodTrial
Completed enrollment in Phase 2a trial of neflamapimod in nfvPPA
nonfluent variant primary progressive aphasia (nfvPPA)source ↗
▼Equity OfferingCorporate
Announced $10 million registered direct offering of 2.5M shares at $4.00 per share
▲Enrollment CompleteNeflamapimodTrial
Completed enrollment in Phase 2a trial in nonfluent variant primary progressive aphasia
nonfluent variant primary progressive aphasiasource ↗
▲Patent GrantedNeflamapimodIP / Competition
Notice of allowance for U.S. patent covering neflamapimod in pure DLB, providing IP protection into 2042
dementia with Lewy bodies (pure DLB)source ↗
◆Oral PresentationPresentation
CervoMed management to participate in fireside chat at H.C. Wainwright Neuro Perspectives Expert Summit
▲Enrollment CompleteNeflamapimodTrial
Enrollment completed in Phase 2a trial of neflamapimod in nfvPPA
Nonfluent/Agrammatic Variant Primary Progressive Aphasia (nfvPPA)source ↗
▼Equity OfferingCorporate
Private placement financing of approximately $10.5 million gross proceeds
◆Trial InitiationNeflamapimodTrial
Initiation of global Phase 3 trial planned
dementia with Lewy bodiessource ↗
▲Manufacturing MilestoneNeflamapimodCMC / Inspection
Manufacture and release of initial Phase 3 clinical drug batch
dementia with Lewy bodiessource ↗
▲Preclinical PoCNeflamapimodPreclinical
Completion of 39-week chronic toxicity study in non-rodent species
dementia with Lewy bodiessource ↗
▲PublicationNeflamapimodPresentation
Peer-reviewed publication validates pharmacological approach of neflamapimod in DLB
dementia with Lewy bodiessource ↗
◆Oral PresentationNeflamapimodPresentation
Presentation of full clinical data from Phase 2b RewinD-LB trial at major scientific conferences
dementia with Lewy bodiessource ↗
▲Enrollment CompleteNeflamapimodTrial
Phase 2a trial in nfvPPA fully enrolled ahead of schedule
nonfluent variant primary progressive aphasiasource ↗
●Dose Finding UpdateNeflamapimodTrial
Neflamapimod 50mg TID dose selected for EXPERTS-ALS trial
amyotrophic lateral sclerosissource ↗
◆Partnership / LicenseNeflamapimodCorporate
CervoMed announced intent to establish strategic partnership to advance neflamapimod into Phase 3 for DLB
dementia with Lewy bodies (DLB)source ↗
▲Patent GrantedNeflamapimodIP / Competition
Notice of allowance for patent covering neflamapimod use in pure DLB
dementia with Lewy bodies (DLB)source ↗
▼Enrollment PausedNeflamapimodTrial
Ended enrollment in Phase 2a RESTORE trial
recovery after acute ischemic strokesource ↗
◆Trial InitiationNeflamapimodTrial
Global pivotal Phase 3 trial initiation planned for neflamapimod in DLB
dementia with Lewy bodiessource ↗
◆Oral PresentationNeflamapimodPresentation
Oral presentation of neflamapimod treatment effects in DLB without AD co-pathology at AD/PD 2026
dementia with Lewy bodiessource ↗
◆Oral PresentationNeflamapimodPresentation
Scientific symposium on advancing drug development in DLB at AD/PD 2026
dementia with Lewy bodiessource ↗
▲First Patient DosedNeflamapimodTrial
Phase 1 healthy volunteer study completed evaluating PK of stable crystal form
dementia with Lewy bodiessource ↗
▲Manufacturing MilestoneNeflamapimodCMC / Inspection
Controlled manufacturing process and stable crystal form of neflamapimod announced
dementia with Lewy bodiessource ↗
▲Other Regulator MilestoneNeflamapimodEx-US Regulatory
Neflamapimod elected for inclusion in UK EXPERTS-ALS platform
amyotrophic lateral sclerosissource ↗
Past FDA Catalysts and PDUFA Decisions
How CRVO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-11 | neflamapimod | Phase 2a data presentation | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 30%
Micro Cap(rank 198 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Neflamapimod Small moleculeNCT07033481 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Phase 2 | ACTIVE NOT_RECRUITING | 20 | Oct 1, 2026 | ||||||
| Neflamapimod Small moleculeNCT06987643 | Moderate to Severe Acute Ischaemic Stroke | Phase 2 | COMPLETED | 90 | Oct 6, 2026 | ||||||
| Neflamapimod Small moleculeCompletedNCT06815965 | Dementia With Lewy Bodies | Phase 2 | COMPLETED | 276 | Mar 25, 2026 | ||||||
| Neflamapimod Small moleculeCompletedNCT03402659 | Alzheimer Disease | Phase 2 | COMPLETED | 161 | Jul 31, 2019 | ||||||
| VX-745 Small moleculeCompletedNCT02423122 | Alzheimer's Disease | Phase 2 | COMPLETED | 32 | Sep 1, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRVO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| neflamapimod Fast TrackOrphan | nonfluent variant primary progressive aphasia (nfvPPA) | Phase 2a | 2026-10-12 | mean reduction in NfL observed over the first 12 weeks; 18 of 25 participants (72%) had elevated NfL levels; mean baseline NfL across all participants was 45.7 pg/mL; mean change in plasma NfL levels was ~ 3.1 pg/mL; mean change in NfL levels was ~ 5.7 pg/mL over 12 weeks in participants with baseline NfL levels at or above the medianRead More | CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BOGER JOSHUA SDirector, 10% Owner | Buy | 955,414 955,414 held | $0.00 | 06/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRVO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % (-50 %) | 11.93 M | 817.12 K |
CRVO Institutional Ownership Trends
CRVO Short Interest
Shares sold short, counted twice a month.
12.45%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
-9.8% vs prior count
3.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
408.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRVO ranks across every disease it competes in
Competitive Position is a premium feature
See how CRVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRVO News
CRVO▼ -20.8%on this news
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
CervoMed announced the publication of two peer-reviewed studies supporting neflamapimod as a potential treatment for dementia with Lewy bodies (DLB). The Phase 2b RewinD-LB trial results indicated that while the primary outcome was not confirmed, significant benefits were observed in specific patient groups. Neflamapimod was well tolerated, with minimal adverse events reported.
Read more →CRVO▼ -22%on this news
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
CervoMed has reported promising initial results from its Phase 2a trial of neflamapimod for treating nonfluent variant primary progressive aphasia (nfvPPA). The trial showed a significant reduction in plasma neurofilament light chain levels over 12 weeks, indicating potential neuronal protection. Further biomarker data is expected in November 2026, with clinical data anticipated in early 2027.
Read more →CRVO▲ +5.1%on this news· ran to +15% by day 3
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed has announced a new 50 mg tablet formulation of neflamapimod, which enhances its pharmacokinetic profile for twice-daily dosing. The FDA has removed the previous drug exposure limit, allowing for a planned 100 mg BID regimen that aims to achieve higher plasma concentrations. These advancements are expected to reduce risks in clinical execution and manufacturing.
Read more →CRVOCervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026. The company will engage in a panel discussion titled 'Frontiers in Neuroscience' and conduct one-on-one meetings. CervoMed is focused on developing treatments for age-related brain disorders, with its lead candidate, neflamapimod, showing promise in clinical trials.
Read more →CRVOCervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
CervoMed announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, which enrolled 25 participants, aims to evaluate the drug's safety and efficacy. Initial biomarker data from the first eight participants will be highlighted, showcasing potential therapeutic benefits.
Read more →CRVOCervoMed to Participate in September Investor Conferences
CervoMed Inc. (NASDAQ: CRVO) has announced its participation in two investor conferences in September 2026. The company will engage in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference and will present at the H.C. Wainwright Global Investment Conference. CervoMed is focused on developing treatments for age-related brain disorders, with its lead candidate, neflamapimod, showing promise in ongoing clinical trials.
Read more →CRVOCervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed reported its second quarter 2026 financial results, highlighting progress in its neflamapimod program for dementia with Lewy bodies (DLB). The drug received Innovation Passport Designation in the UK, and new analyses presented at AAIC 2026 support its treatment effects. The company aims to secure a strategic partnership to advance neflamapimod into Phase 3 trials.
Read more →CRVOCervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
CervoMed Inc. will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The discussion will focus on recent advancements in the clinical development of neflamapimod, the company's lead drug candidate for age-related brain disorders. CervoMed has completed a Phase 2b trial and is preparing for a Phase 3 trial, pending partnership or financing.
Read more →CRVO▲ +7.7%on this newsshared move
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed's neflamapimod has received the Innovation Passport designation under the UK's Innovative Licensing and Access Pathway for treating Dementia with Lewy Bodies (DLB). This designation aims to expedite patient access to innovative therapies addressing significant unmet needs. The company plans to collaborate with UK regulatory authorities as it prepares for a Phase 3 trial.
Read more →CRVO▼ -6.9%on this news
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed presented new data on neflamapimod at AAIC 2026, highlighting its potential in treating Dementia with Lewy Bodies (DLB). The analyses from the Phase 2b trial showed a durable treatment effect and supported the dosing strategy for an upcoming Phase 3 study. However, challenges in replicating earlier positive results were noted due to patient selection and drug concentration issues.
Read more →CRVO▲ +9.7%on this newsshared move
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
CervoMed Inc. has completed enrollment in its Phase 2a study of neflamapimod for treating nonfluent variant primary progressive aphasia (nfvPPA), a type of frontotemporal dementia. The study aims to assess the drug's safety and efficacy, with interim biomarker data expected to be presented at the upcoming CTAD conference. This development highlights the urgency for effective treatments in a condition currently lacking approved therapies.
Read more →CRVOCervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
CervoMed Inc. will present five studies on neflamapimod at the AAIC 2026, showcasing its potential in treating dementia with Lewy bodies (DLB). The findings highlight the drug's impact on disease progression and biomarkers. Despite the lack of approved treatments for DLB, the data from clinical trials suggest neflamapimod could significantly benefit patients.
Read more →CRVO▼ -9.9%on this news· ran to -21% by day 1
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Inc. has completed a registered direct offering, raising $10 million by selling 2.5 million shares at $4.00 each. The funds are intended for working capital and corporate purposes. The company has also aligned with the FDA on a potential registration path for its lead drug candidate, neflamapimod, in treating dementia with Lewy bodies.
Read more →CRVO▼ -43.2%on this news· ran to -56% by day 3shared move
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
CervoMed Inc. has announced a registered direct offering of 2.5 million shares of common stock at $4.00 per share, aiming to raise $10 million. The offering is expected to close around June 22, 2026, pending customary conditions. Proceeds will be used for working capital and corporate purposes, supporting the company's ongoing clinical trials and development efforts.
Read more →CRVO▲ +11.3%on this newsshared move
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
CervoMed Inc. has received a notice of allowance for a new patent protecting the use of neflamapimod in treating dementia with Lewy bodies without significant Alzheimer’s pathology. This patent is expected to provide protection until 2042. Currently, there are no approved treatments for this condition, and the company is working towards initiating a Phase 3 trial, contingent on partnerships and funding.
Read more →CRVOCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
CervoMed Inc. will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026. The company will engage in a fireside chat and one-on-one investor meetings. CervoMed is focused on developing treatments for age-related brain disorders, including its lead candidate, neflamapimod, which has shown promise in clinical trials.
Read more →CRVO▼ -22.1%on this newsshared move
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
CervoMed Inc. announced a $10.5 million private placement to extend its cash runway into 2027 and focus on establishing a partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies (DLB). The company has achieved significant progress in clinical trials and is aligned with regulatory bodies on a potential registration path for neflamapimod. Upcoming milestones include data from ongoing trials in related neurological disorders.
Read more →CRVO▼ -11.6%on this news
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Read more →CRVOCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Read more →CRVOCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Read more →About CervoMed Inc.
Headquarters20 PARK PLAZA, BOSTON, MA, 02116
BIOPHARMAWATCH ELITE PLUS
Trade the next CRVO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime